Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P00441: Variant p.Gly94Ala

Superoxide dismutase [Cu-Zn]
Gene: SOD1
Feedback?
Variant information Variant position: help 94 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glycine (G) to Alanine (A) at position 94 (G94A, p.Gly94Ala). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to small size and hydrophobic (A) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In ALS1; increases tendency to form fibrillar aggregates; ubiquitinated by RNF19A; ubiquitinated by MARCHF5. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 94 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 154 The length of the canonical sequence.
Location on the sequence: help GPKDEERHVGDLGNVTADKD G VADVSIEDSVISLSGDHCII The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 154 Superoxide dismutase [Cu-Zn]
Binding site 81 – 81
Binding site 84 – 84
Modified residue 92 – 92 N6-succinyllysine
Modified residue 99 – 99 Phosphoserine
Modified residue 103 – 103 Phosphoserine
Modified residue 106 – 106 Phosphoserine
Modified residue 108 – 108 Phosphoserine
Disulfide bond 58 – 147
Mutagenesis 81 – 81 H -> A. Loss of zinc binding and enhanced tendency to form aggregates; when associated with A-84.
Mutagenesis 81 – 81 H -> S. Destabilization of dimer and loss of zinc binding; when associated with S-84.
Mutagenesis 84 – 84 D -> A. Loss of zinc binding and enhanced tendency to form aggregates; when associated with A-81.
Mutagenesis 84 – 84 D -> S. Destabilization of dimer and loss of zinc binding; when associated with S-81.
Mutagenesis 112 – 112 C -> S. Enhances formation of fibrillar aggregates in the absence of bound zinc; when associated with S-7; S-58 and S-147.
Helix 92 – 94



Literature citations
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.
Rosen D.R.; Siddique T.; Patterson D.; Figlewicz D.A.; Sapp P.; Hentati A.; Donaldson D.; Goto J.; O'Regan J.P.; Deng H.-X.; Rahmani Z.; Krizus A.; McKenna-Yasek D.; Cayabyab A.; Gaston S.M.; Berger R.; Tanzi R.E.; Halperin J.J.; Herzfeldt B.; van den Bergh R.; Hung W.-Y.; Bird T.; Deng G.; Mulder D.W.; Smyth C.; Laing N.G.; Soriano E.; Pericak-Vance M.A.; Haines J.; Rouleau G.A.; Gusella J.S.; Horvitz H.R.; Brown R.H. Jr.;
Nature 362:59-62(1993)
Cited for: VARIANTS ALS1 ARG-38; VAL-39; ASP-42; SER-42; ARG-44; ARG-86; ALA-94; CYS-94; GLY-101; VAL-107 AND THR-114; Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase.
Deng H.-X.; Hentati A.; Tainer J.A.; Iqbal Z.; Cayabyab A.; Hung W.-Y.; Getzoff E.D.; Hu P.; Herzfeldt B.; Roos R.P.; Warner C.; Deng G.; Soriano E.; Smyth C.; Parge H.E.; Ahmed A.; Roses A.D.; Hallewell R.A.; Pericak-Vance M.A.; Siddique T.;
Science 261:1047-1051(1993)
Cited for: VARIANTS ALS1 VAL-5; ARG-38; VAL-39; ASP-42; SER-42; ARG-44; ARG-86; ALA-94; CYS-94; GLY-101; VAL-107; THR-114; PHE-145 AND GLY-149; Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity.
Niwa J.; Ishigaki S.; Hishikawa N.; Yamamoto M.; Doyu M.; Murata S.; Tanaka K.; Taniguchi N.; Sobue G.;
J. Biol. Chem. 277:36793-36798(2002)
Cited for: CHARACTERIZATION OF VARIANTS ALS1 ARG-38; ARG-47; ARG-86 AND ALA-94; INTERACTION WITH RNF19A; UBIQUITINATION; SOD1 and amyotrophic lateral sclerosis: mutations and oligomerization.
Banci L.; Bertini I.; Boca M.; Girotto S.; Martinelli M.; Valentine J.S.; Vieru M.;
PLoS ONE 3:E1677-E1677(2008)
Cited for: CHARACTERIZATION OF VARIANTS ALS1 ARG-55; ALA-91; ALA-94; ASP-94; MET-98 AND PHE-145; Mitochondrial ubiquitin ligase MITOL ubiquitinates mutant SOD1 and attenuates mutant SOD1-induced reactive oxygen species generation.
Yonashiro R.; Sugiura A.; Miyachi M.; Fukuda T.; Matsushita N.; Inatome R.; Ogata Y.; Suzuki T.; Dohmae N.; Yanagi S.;
Mol. Biol. Cell 20:4524-4530(2009)
Cited for: CHARACTERIZATION OF VARIANTS ALS1 ARG-86 AND ALA-94; UBIQUITINATION BY MARCH5; SUBCELLULAR LOCATION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.